Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.

PLoS One · 2022 · PMC8820624 · PMID 35130283

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Out of 13 patients having at least 2 mutations in separate genes, 8 patients showed a trend that was similar to the mutation in TP53 , the other 4 genes showed a different trend: KEM-016 only had one detectable mutation in plasma at postoperative day 1 ( TP53 ) the other mutation was only detected in tissue.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.